Five things for pharma marketers to know: Friday, October 21, 2016

1. Sen. Bernie Sanders (I-VT) and Rep. Elijah Cummings (D-MD) requested information from Ariad Pharmaceuticals about price hikes for Iclusig, a leukemia drug. The price of the drug has increased by $80,000 in recent years. (AP)

2. Abbott Laboratories, which is Mylan's largest shareholder, wrote down the value of its investment by $947 million based on declines in Mylan's share price. Mylan has faced backlash over the pricing of its EpiPen, an allergy autoinjector. (WSJ)

3. The rebranding of CVS Health, including the decision to stop selling cigarettes in its retail stores, improved the company's reputation among health influencers and prompted 260,000 people to ask for advice about smoking cessation from its pharmacies. (Ad Age)

4. Patients who received inaccurate test results from Theranos made changes to their health based on those results, including adjusting and stopping medications and changing their diets. Theranos shut down its blood-testing facilities this year after sustained criticism from the media and the loss of a federal license. (WSJ)  

5. Physicians from the Mayo Clinic say online health advice is often inconclusive. A study found none of the major health sites listed all the symptoms that would help an individual  accurately triage a condition, while a third of the sites did not list any key symptoms. (NYT)